Real-World Clinical and Economic Outcomes Among Patients with Localized Prostate Cancer Treated with External Beam Radiation Therapy Across Different Risk Stratifications in the United States
Authors:
- Neal ShoreNSNeal Shore
- Benjamin LowentrittBLBenjamin Lowentritt
- Charmi PatelCPCharmi Patel
- Sabree BurbageSBSabree Burbage
- Frederic KinkeadFKFrederic Kinkead
- Carmine RossiCRCarmine Rossi
- Francesca LeeFLFrancesca Lee
- Dominic PilonDPDominic Pilon
- Lawrence KarshLKLawrence Karsh
- Gordon BrownGBGordon Brown
Open Access
- 30 October 2026
- journal article
- Published by The Journal of Health Economics and Outcomes Research in Journal of Health Economics and Outcomes Research
- Vol. 13 (2) , 222-230
Abstract
Background: Despite the availability of several androgen receptor pathway inhibitors for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC), there has been a lack of head-to-head randomized clinical trials to evaluate their comparative efficacy in this population. Objective: This real-world study provides a comprehensive and robust comparison of the decline in prostate-specific antigen ≥90% (PSA90) among patients with mCSPC who initiated apalutamide or abiraterone acetate in the United States. Methods: Clinical data were collected from US community urology practices by Precision Point Specialty Analytics and linked with administrative claims from the Komodo Health Solutions Research Database. Patients with mCSPC were included in apalutamide or abiraterone acetate cohorts based on their first dispensation/paid claim on or after September 17, 2019 (index date), and followed to the earliest of treatment discontinuation or switch, end of insurance/clinical activity, or end of data availability (Dec. 31, 2023). Inverse probability of treatment weighting balanced potentially confounding patient characteristics. PSA90 response by 6 months post index was compared between the cohorts using weighted Kaplan-Meier analysis and time to PSA90 response was compared using a weighted Cox model with a time-varying treatment effect. Results: The study included 1351 patients in the apalutamide cohort and 1003 patients in the abiraterone acetate cohort. By 6 months, 61.4% of the weighted apalutamide cohort and 45.9% of the weighted abiraterone acetate cohort achieved a PSA90 response. Compared with abiraterone acetate, patients treated with apalutamide were 73% more likely to achieve a PSA90 response at 6 months (weighted hazard ratio, 1.73; 95% confidence interval, 1.44-2.08; P < .001). The median time to PSA90 response was 3.8 and 8.7 months in the apalutamide and abiraterone acetate cohorts, respectively. Conclusions: The results of this study confirm that patients with mCSPC treated with apalutamide have significantly higher rates of PSA90 response compared with abiraterone acetate after 6 months of treatment. Real-world evidence highlights apalutamide as an important treatment option to improve the prognosis of patients with mCSPC.Keywords
This publication has 18 references indexed in Scilit:
- Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trialWorld Journal of Urology, 2025
- Prostate Cancer, Pathophysiology and Recent Developments in Management: A Narrative ReviewCurrent Oncology Reports, 2024
- Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future PerspectivesClinical Genitourinary Cancer, 2024
- Differences in real‐world outcomes by risk classification for localized prostate cancer patients after radiation therapyThe Prostate, 2024
- Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratificationProstate Cancer and Prostatic Diseases, 2023
- Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery systemCancer, 2023
- Cost of cancer management by stage at diagnosis among Medicare beneficiariesCurrent Medical Research and Opinion, 2022
- Systemic treatments for high-risk localized prostate cancerNature Reviews Urology, 2018
- Impact of subsequent metastases on costs and medical resource use for prostate cancer patients initially diagnosed with localized diseaseCancer, 2017
- Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational ResearchCommunications in Statistics - Simulation and Computation, 2009